CLS is committed to providing the media with timely and accurate information related to California’s life sciences ecosystem. CLS welcomes all media inquiries from news organizations and reporters. Members of the media interested in speaking with CLS opinion leaders on issues of public policy, life sciences innovation, or issues related to the life sciences ecosystem in California, please contact our communication department.
Media Contact: [email protected]
Meet The Six FAST Startups Innovating This Spring With The Guidance Of Life Sciences Advisors
Mar 30, 2021
As part of our ongoing programs to support early-stage companies, the Spring 2021 FAST Advisory Program just began, providing coaching and business advising for six startups.
Read More CLS Requests Support For Legislation To Restore R&D Tax Credit To Assist With The State’s Economic Recovery
Mar 26, 2021
The California Life Sciences Association (CLSA) sponsored and introduced Assembly Bill (AB) 593, with Assemblymember Cottie Petrie-Norris (AD 74) which reinstates the Research and Development (R&D) Tax Credit and Net Operating Loss (NOL) deductions for life sciences companies in California for tax years 2021 and 2022.
Read More CLSA Welcomes Our Newest Members!
Mar 24, 2021
CLSA’s diverse membership base of life sciences companies and organizations grows each month as we welcome the world’s most promising entrepreneurial start-ups, research institutions, investors and the full spectrum of life sciences, therapeutics, medical device and diagnostic companies that are addressing global health challenges; digital health innovators that are using technology to transform healthcare; agricultural companies improving the safety and security of our food supply; and bioindustrial organizations energizing a more sustainable world.
Read More New Data Show Foreign Reference Drug Pricing Proposals Would Reduce The Development Of New Innovative Medicines In California By 88%
Mar 24, 2021
Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.
Read More Biotech Takes On Racial And Social Equity. Are The Efforts Sustainable?
Mar 23, 2021
From holding Covid-19 vaccination events in San Francisco’s Tenderloin neighborhood to building programs that target longstanding inequities, the Bay Area biotech industry is stepping into high-profile social issues like never before.
Read More CLSA/CLSI Announce Initiation Of Mentoring, Coaching And Professional Development Programs To Help Address Gaps In Representation And Inequity In The California Life Sciences Industry
Mar 18, 2021
The California Life Sciences Association (CLSA)/California Life Sciences Institute (CLSI) announced the creation of the Racial & Social Equity (RSE) Initiative, part of a multi-year program, funded by CLSA/CLSI member companies, with the goal of helping close the gaps in inequity and create a more diverse industry. The RSE Initiative has already surpassed its initial fundraising budget of $1M, with a goal of sustaining 3-year commitments of $1M annually.
Read More